Skip to main content

Table 5 The result of multivariate analysis on group 4 and 5

From: The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas

4 N (%) Age median
(range)
Median survival years (95% CI) Univariate analysis Multivariate analysis
     Hazard ratio 95% CI p Value Hazard ratio 95% CI p Value
Group 4
AA, IDH-wildtype 15 51 (26–72) 18.1 (0.000–36.278)       
TERTp-mutant 3 69.0 (62–72) 8.0 (0.000–20.002) 0.341 0.85–1.377 1.113 1.11 0.116–10.608 0.928
TERTp-wildtype 12 46.5 (27–58) 18.1 (0.000–46.107)       
ATRX-mutant 9 44.5 (27–69) 28.2 (0.954–55.446) 0.555 0.182–1.687 0.299 0.731 0.214–2.498 0.618
ATRX-wildtype 6 54 (41–72) 11.7 (6.733–16.667)       
MGMTp-methylated 8 48.5926–62) 28.2 (18.448–37.952) 1.109 0.365–3.367 0.856 1.076 0.261–4.434 0.919
MGMTp-unmythylated 7 54 (27–72) 7.9 (2.218–13.582)       
Age < 55 years old 10 41.5 (26–54.9) 28.2 (8.676–47.724) 4.027 1.048–15.472 0.043 0.296 0.042–2.107 0.224
Age > 55 years old 5 62 (57–69) 8.0 (7.785–8.215)       
Group 5
GBM, IDH-wildtype 52 55 (17–79) 14.5 (10.378–18.622)       
​TERTp-mutant 41 58 (36–79) 16.4 (13.012–19.516) 0.768 0.390–1.513 0.445 2.111 1.016–4.389 0.045
​TERTp-wildtype 11 42 (31–69) 13.0 (1.021–25.039)       
ATRX-mutant 5 58 (29–69) 13.0 (0.513–25.547) 0.682 0.269–1.733 0.422 1.269 0.499–3.231 0.617
ATRX-wildtype 47 55 (31–79) 16.4 (12.773–20.027)       
MGMTp-methylated 26 57.5 (29–79) 18.3 (12.671–23.989) 0.579 0.326–1.031 0.061 0.665 1.399–5.078 0.002
MGMTp-unmythylated 26 51 (36–79) 13.0 (9.407–16.653)       
Age < 55 years old 24 45 (29–54.9) 20.8 (13.599–28.001) 1.843 1.047–3.331 0.035 3.090 1.578–6.049 0.001
Age > 55 years old 28 67 (55.3–79) 10.5 (5.703–15.297)       
\